SAN DIEGO & BURLINGTON, N.C.--(BUSINESS WIRE)--
Illumina, Inc. (NASDAQ: ILMN) and Laboratory Corporation of America®
Holdings (LabCorp®) (NYSE: LH), the world's leading healthcare
diagnostics company, today announced that on October 5, 2016, the
Düsseldorf Regional Federal Court in Germany issued a preliminary
injunction order against amedes MVZ Trägergesellschaft Göttingen mbH and
a related company (collectively "amedes"). The order requires amedes to
immediately stop performing the Fetalis® non-invasive prenatal screening
test in Germany, which is based on technology from Ariosa Diagnostics,
Inc.
The Application for the Grant of a Preliminary Injunction against amedes
was filed by Sequenom, Inc., a wholly-owned subsidiary of LabCorp®, as
patent owner of EP 0 994 963. The patent relates to the detection of
cell-free fetal DNA for non-invasive prenatal screening. Illumina
exclusively licenses the patent in the field of in vitro diagnostics.
Illumina and Sequenom have significant intellectual property rights in
the area of non-invasive prenatal screening and will continue to enforce
those rights when appropriate. This suit adds to prior patent
infringement suits filed against others in Europe, Australia and the
United States.
About Illumina
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture and other emerging segments. To learn more, visit www.illumina.com
and follow @illumina.
About LabCorp®
Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500
company, is the world's leading healthcare diagnostics company,
providing comprehensive clinical laboratory and end-to-end drug
development services. With a mission to improve health and improve
lives, LabCorp delivers world-class diagnostic solutions, brings
innovative medicines to patients faster and develops technology-enabled
solutions to change the way care is provided. With net revenue in excess
of $8.5 billion in 2015, LabCorp's 50,000 employees serve clients in 60
countries. To learn more about LabCorp, visit www.labcorp.com,
and to learn more about Covance Drug Development, visit www.covance.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006293/en/
